Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa TrialBryan Myung
In a recently published microcosting analysis using trial healthcare resource utilization data, our colleagues estimated post-infusion costs with the chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel), for relapsed/refractory multiple myeloma patients over a 2-year period. Findings suggest most costs were incurred in the initial treatment period of the first month post-infusion and then tapered off to a nominal, incremental monthly cost over the remaining 23 months captured. Future research is needed to assess if ide-cel post-infusion costs are lower in the real-world setting.
Citation: McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell TB, Patwardhan P. Post-Infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial. Adv Ther, 2023. https://doi.org/10.1007/s12325-023-02623-w